CTLA4 and non-small cell lung carcinoma: For another, the pooled population was approximately several times the size for NSCLC patients than for SCLC patients and PD-1 inhibitor than for CTLA-4 inhibitor so that uncertain outcomes were generated by the size of the difference, which made it impossible to obtain specific conclusions.